Tech Company Financing Transactions
NKT Therapeutics Funding Round
NKT Therapeutics closed a $2 million venture capital round on 9/30/2012. Investors included SV Health Investors and private investors.
Transaction Overview
Company Name
Announced On
9/30/2012
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Undisclosed
Investors
SV Health Investors (Michael Ross)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
58 Deborah Sampson St.
Sharon, MA 02067
USA
Sharon, MA 02067
USA
Phone
Website
Email Address
Overview
NKT Therapeutics, Inc. is a biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. NKT cells are a rare but central component of the human immune system which plays a pivotal role in human health and disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Mashal
Chief Scientific Officer
Robert Schaub
VP - Finance
Ron Goldstein
Browse more venture capital transactions:
Prev: 9/30/2012: Ultragenyx Pharmaceutical venture capital transaction
Next: 9/30/2012: CliQr Technologies venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record funding rounds that are announced publicly. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs